Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

PHASE3CompletedINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

October 15, 2002

Primary Completion Date

October 19, 2011

Study Completion Date

September 19, 2013

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

prednisone

Given orally

DRUG

thalidomide

Given orally

Trial Locations (18)

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

E1C 6Z8

The Moncton Hospital, Moncton

E2L 4L2

Atlantic Health Sciences Corporation, Saint John

AIB 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's

B3H 1V7

QEII Health Sciences Center, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

N6A 4L6

London Regional Cancer Program, London

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

H1T 2M4

Hopital Maisonneuve-Rosemont, Montreal

H2W 1S6

McGill University - Dept. Oncology, Montreal

G1S 4L8

CHA-Hopital Du St-Sacrement, Québec

J1H 5N4

Centre hospitalier universitaire de Sherbrooke, Sherbrooke

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Eastern Cooperative Oncology Group

NETWORK

lead

NCIC Clinical Trials Group

NETWORK